---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-278325"
form_type: "8-K"
ticker: "QTTB"
cik: "0001661998"
company_name: "Q32 Bio Inc."
filed_at: "2023-11-16T23:59:59+00:00"
generated_at: "2026-06-08T01:15:07.918517+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Homology Medicines to merge with Q32 Bio; Q32 shareholders to own 75%, combined company targets autoimmune pipeline

## Summary
- Homology issues stock to Q32 holders; pre-merger Homology shareholders own ~25%, Q32 ~75%; CVR issued for legacy asset proceeds.
- Concurrent $42M private placement (OrbiMed, Atlas, Bristol Myers Squibb, etc.) to fund Phase 2 trials of bempikibart and ADX-097.
- Combined company expects ~$115M cash at close, runway to mid-2026; Homology discontinues R&D, including PKU gene therapy HMI-103.
- Q32 reacquired worldwide rights to bempikibart (anti-IL-7Rα) from Amgen; Phase 2 topline data for atopic dermatitis & alopecia areata in 2H 2024.
- ADX-097 (tissue-targeted complement inhibitor) Phase 1 safety positive; Phase 2 basket trial start expected with proof-of-concept data by year-end 2024.

## SEC filing metadata
- accession: 0001193125-23-278325
- form_type: 8-K
- ticker: QTTB
- cik: 0001661998
- company_name: Q32 Bio Inc.
- filed_at: 2023-11-16T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661998/000119312523278325/0001193125-23-278325-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661998/000119312523278325/d350321d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-278325
- JSON: https://secwatch.observer/filing/0001193125-23-278325.json
- Plain text: https://secwatch.observer/filing/0001193125-23-278325.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.